

# ASX Announcement



Medibio Limited – 3 October 2018

## **Medibio Releases Corporate Health Product, ilumen™**

**Sydney, Australia and Minneapolis, MN USA – 3 October 2018: Medibio Limited (MEB or the Company)(ASX: MEB)(OTCQB: MDBIF), a mental health technology company, today announced the release of ilumen™, its product and platform for corporate customers.**

ilumen™ is a corporate wellness product providing employers the ability to offer biometric analysis and objective, data-driven feedback along with a mental wellness assessment to their employees. The upgraded platform allows employees to access and monitor this data from their personal devices, measuring and tracking biometrics through the use of wearable technology over a period of time. Participants can proactively learn about coping strategies, resources, and personal development plans to better manage stress and strain from life and work.

Employee-specific features of the ilumen™ platform include:

- Access to personalised resources for support and education to help improve mental wellness
- Ability to monitor digital biometric changes and identify how and when personal lifestyle modifications influence mental wellness
- Improved biometric integration with supported Garmin and Fitbit wearable devices

ilumen™ provides employers with access to a de-identified, aggregate-level dashboard to support informed decision-making, improved team performance, and increased employee well-being. Many companies have health care plans in place to address physical health. Medibio's platform allows employers to extend support to cover mental health, ushering in a new era of workplace wellness.

The ilumen™ product is the latest advancement of Medibio's Corporate Health offering with a core focus on designing products and services to help organisations optimise workforce performance, minimise risk, and provide better care to the people that power their businesses.

"ilumen™ is an advancement in corporate mental health that provides employers and participating employees with the ability to track mental wellness through digital biometrics and personalized assessments," commented Brian Mower, Interim CEO for Medibio. "It's time for corporations to use objective data to better understand and enhance employee mental wellness."

The ilumen™ product is currently available for our corporate customers via Google and Apple app stores, as well as through the web.

# ASX Announcement



Medibio Limited – 3 October 2018

## **Award Recognition**

Medibio has been chosen as a finalist in the Health Services Business of the Year category at the 2018 Optus My Business Awards, the premier event of the year for small and medium-sized enterprises. The awards cover 28 categories, acknowledges best practice within a particular industry sector, as well as individual business leaders, excellence in customer service and achievements in innovation, corporate social responsibility and workplace culture. Winners will be announced 29 November 2018.

- END -

## **About Medibio Limited**

Medibio (ASX: MEB) (OTCQB: MDBIF) is a mental health technology company that has pioneered the use of objective digital biomarkers to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company was founded in Australia, with offices located in Melbourne (Vic), Perth (Wa) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on [www.otcm Markets.com](http://www.otcm Markets.com) and [www.asx.com.au](http://www.asx.com.au)

### **Further Information:**

Website: [www.medibio.com.au](http://www.medibio.com.au)

### **Medibio Enquiries:**

Josh Purdy  
Senior Public Relations Manager  
Medibio Limited  
[josh.purdy@medibio.com.au](mailto:josh.purdy@medibio.com.au)  
T: +1 952 314 1216

### **Australian Media Enquiries:**

Peter Taylor  
NWR Communications  
[peter@nwrcommunications.com.au](mailto:peter@nwrcommunications.com.au)  
T: +61 (0) 412 036 231